Nuclear PRMT5 is a biomarker of sensitivity to tamoxifen in ERα+ breast cancer

Nuclear PRMT5 is a biomarker of sensitivity to tamoxifen in ERα+ breast cancer

Abstract Endocrine therapies targeting estrogen signaling, such as tamoxifen, have significantly improved management of estrogen receptor alpha (ERα)‐positive breast cancers. However, their efficacy is limited by intrinsic and acquired resistance to treatment, and there is currently no predictive ma...

Full description

Bibliographic Details
Main Authors: Coralie Poulard, Thuy Ha Pham, Youenn Drouet, Julien Jacquemetton, Ausra Surmielova, Loay Kassem, Benoite Mery, Christine Lasset, Jonathan Reboulet, Isabelle Treilleux, Elisabetta Marangoni, Olivier Trédan, Muriel Le Romancer
Format: Article
Language:English
Published: Springer Nature 2023-08-01
Series:EMBO Molecular Medicine
Subjects:
arginine methylation
estrogen receptor
PRMT5
resistance
tamoxifen
Online Access:https://doi.org/10.15252/emmm.202217248

Internet

https://doi.org/10.15252/emmm.202217248

Similar Items